161 related articles for article (PubMed ID: 24442606)
1. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?
Wattjes MP; Killestein J
Ann Neurol; 2014 Mar; 75(3):462. PubMed ID: 24442606
[No Abstract] [Full Text] [Related]
2. Reply: To PMID 24242357.
Fine AJ; Sorbello A; Kortepeter C
Ann Neurol; 2014 Mar; 75(3):462-3. PubMed ID: 24443375
[No Abstract] [Full Text] [Related]
3. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
5. Natalizumab-induced PML: can the beast be tamed?
Hohlfeld R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818
[No Abstract] [Full Text] [Related]
6. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
7. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
Arnaud FX; Hissene A; Métivier D; Dutasta F; Berets O; N'guema B; A'teriitéhau C; Baccialone J; Potet J
J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Décard BF; Haghikia A; Tönnes C; Thöne J; Lukas C; Chan A; Gold R
Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
12. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
[No Abstract] [Full Text] [Related]
13. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
Gibelin N; Daelman L; Goulipian S; Wynckel A; Chaunu MP; Tourbah A
Rev Neurol (Paris); 2014 Jan; 170(1):48-50. PubMed ID: 24139244
[No Abstract] [Full Text] [Related]
14. To PLEX or not to PLEX in natalizumab-associated PML.
Tyler KL; Vollmer TL
Neurology; 2017 Mar; 88(12):1108-1109. PubMed ID: 28228561
[No Abstract] [Full Text] [Related]
15. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
16. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
17. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
18. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
19. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
20. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
[Next] [New Search]
